CytomX Therapeutics, Inc. To Present Probody Overview At The Credit Suisse Antibody Day
SOUTH SAN FRANCISCO, Calif., May 5, 2015 /PRNewswire/ -- CytomX, a biotechnology company developing Probody therapeutics for the treatment of cancer, today announced that Sean McCarthy, D. Phil., chief executive officer, will present at the Credit Suisse Antibody Day in New York at 1:15 p.m. EDT on Wednesday, May 6. Dr. McCarthy will present an overview of CytomX's Probody pipeline, including the company's Precision cancer immunotherapy and Probody drug conjugate programs.
About CytomX Therapeutics
CytomX Therapeutics develops Probody therapeutics for the treatment of cancer. Probodies are masked antibodies that remain inert in healthy tissue but are activated specifically in the disease microenvironment. The Probody approach is designed to blunt systemic toxicities associated with antibodies and expand the therapeutic window of these drugs, unlocking new therapeutic targets. The Company is initially focusing this highly innovative platform to discover and develop new immunotherapy and antibody drug conjugate therapies to treat areas of major unmet medical need in oncology. CytomX has attracted multiple strategic collaborations with industry-leading pharmaceutical companies including Pfizer Inc., ImmunoGen and Bristol-Myers Squibb. CytomX is led by a seasoned and proven management team and is financed by leading life science investors, including Third Rock Ventures, Canaan Partners, Roche Venture Fund and Pfizer Venture Investments. For more information, please visit www.cytomx.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/cytomx-to-present-probody-overview-at-the-credit-suisse-antibody-day-300077415.html
SOURCE CytomX Therapeutics